StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)

Close on Nov 16, 2026Market cap $303.43MP/E –Yield –

Autolus Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Autolus Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -210.8%. For fiscal 2025 it was -358.9%, against -2385.6% the year before. The highest annual figure on record is -358.9% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-358.9%+2026.8
FY2024Dec 31, 2024-2385.6%+8197.5
FY2023Dec 31, 2023-10583.1%−6494.0
FY2018Sep 30, 2018-4089.1%−2705.8
FY2017Sep 30, 2017-1383.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ2 2026Jun 30, 2026-95.9%+196.6
Q1 FY2026CQ1 2026Mar 31, 2026-227.0%+499.3
Q4 FY2025CQ4 2025Dec 31, 2025-298.3%+261301.7
Q3 FY2025CQ3 2025Sep 30, 2025-337.9%+46.1
Q2 FY2025CQ2 2025Jun 30, 2025-292.6%+14529.7
Q1 FY2025CQ1 2025Mar 31, 2025-726.3%+12769.9
Q4 FY2024CQ4 2024Dec 31, 2024-261600.0%−250190.8
Q1 FY2024CQ1 2024Mar 31, 2024-384.1%–
Q1 FY2021CQ1 2021Mar 31, 2021-14822.3%–
Q2 FY2020CQ2 2020Jun 30, 2020-13496.2%–
Q1 FY2020CQ1 2020Mar 31, 2020-11409.2%–

More Autolus Therapeutics figures

See a number that looks wrong?